Pharmacoeconomic review report : Glecaprevir / pibrentasvir (Maviret) (AbbVie corporation)

Pharmacoeconomic review report Glecaprevir / pibrentasvir (Maviret) (AbbVie corporation)

Glecaprevir/pibrentasvir (GP) is a fixed-dose combination of two pan-genotypic direct-acting antiviral (DAA) drugs: glecaprevir, a nonstructural viral protein 3/4A (NS3/4A) protease inhibitor; and pibrentasvir, a nonstructural viral protein 5A (NS5A) inhibitor. GP is indicated for the treatment of a...

Descripción completa

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Ottawa (ON) : CADTH 2018.
Colección:Common drug review clinical review report.
Materias:
Antiviral agents.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820269706719
Tabla de Contenidos:
  • Abbreviations
  • Executive Summary
  • Background
  • Summary of Identified Limitations and Key Results
  • Conclusions
  • Information on the Pharmacoeconomic Submission
  • Summary of the Manufacturer's Pharmacoeconomic Submission
  • Manufacturer's Base Case
  • Summary of Manufacturer's Sensitivity Analyses
  • Limitations of Manufacturer's Submission
  • CADTH Common Drug Review Reanalyses
  • Patient Input
  • Issues for Consideration
  • Conclusions
  • Appendix 1. Cost Comparison
  • Appendix 2. Additional Information
  • Appendix 3. Reviewer Worksheets
  • References.

Ejemplares similares